Status:

UNKNOWN

Role and Expression of MXRA5 in Placental Connective Tissue Remodelling in Preeclampsia

Lead Sponsor:

Assiut University

Conditions:

Pre-Eclampsia

Eligibility:

FEMALE

20-40 years

Brief Summary

1. To measure the level of expression of MXRA5 and ANXA4 genes in preeclampsia (PE). 2. To detect the effect of heavy metals (lead (Pb) and arsenic (AR)) on these two genes in the pathology of PE. 3. ...

Detailed Description

* Preeclampsia (PE) is a diverse multisystem syndrome defined as a new onset of hypertension along with evidence of significant multiorgan dysfunction in previously normotensive women 20 weeks of gest...

Eligibility Criteria

Inclusion

  • Gestational age is \>28 weeks.
  • Clinically diagnosed PE with blood pressure (≥140/90 mmHg) and proteinuria (≥300mg/dl).
  • Healthy pregnant women (age matched control group).

Exclusion

  • Gestational diabetes.
  • Pregestational hypertension (essential hypertension) or proteinuria.
  • Systemic illness.
  • Vaginal infection.
  • Major known fetal or chromosomal anomalies.
  • Multiple gestations.
  • Intrauterine infections.
  • Preterm premature rupture of membranes.
  • Sepsis.
  • Fever.
  • Colitis ulcerosa.
  • Crohn's disease.
  • Chronic renal disease.
  • Rheumatic disease.

Key Trial Info

Start Date :

April 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

May 1 2021

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04287998

Start Date

April 1 2020

End Date

May 1 2021

Last Update

February 27 2020

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.